ICMR begins study on vaccine for people with poor immunity

Indian Council of Medical Research (ICMR), the country’s top health research body, has initiated a study to evaluate the effectiveness of Covid-19 vaccines in immunocompromised people. Experts say the results are likely in the next six months. The study includes some people with kidney related problems and some on dialysis, among others, they said.

“This way, we will get to know the magnitude of the problem,” said J Muliyil, a member of National Technical Advisory Group on Immunisation (NTAGI).

The study will see how immunocompromised people are responding to existing Covid-19 vaccines, including Covishield and Covaxin. It will also evaluate the effect of a booster shot on these people when it is the same as the one given earlier and also when it’s a different vaccine.

“The study will evaluate how they are responding to vaccines and how giving them a booster dose of the same vaccine and a different vaccine will work,” said Muliyil.

Prime Minister Narendra Modi on Saturday announced that booster shots should be administered to health and frontline workers and those above 60 with comorbidities from January 10. He also said vaccinations will begin for children between 15 and 18 years from January 3.

While the announcement comes as a relief to many, experts say data is needed.

“We have to see whether people who are immunocompromised due to associated disease conditions cannot mount enough immune response. Studies are needed to understand the same and data is generated to see the response of the available vaccines in immunocompromised people,” said an expert at ICMR.

  • Related Posts

    Andelyn Biosciences partners with Queen’s University to develop and manufacture gene therapy AAV9-GM2 to treat GM2 gangliosidoses

    Andelyn bio sciences Inc, a leading patient-focused cell and gene therapy Contract Development and Manufacturing Organization (CDMO), has partnered with Queen’s University to develop and manufacture AAV9-GM2, a gene therapy…

    Cellution Biologics completes acquisition of SimpliDerm business for US$ 8 million from Elutia

    Cellution Biologics Inc, a biologics company focused on developing, manufacturing and commercializing advanced human tissue-based products, announced the completion of its acquisition of the SimpliDerm hydrated human acellular dermal matrix…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    Andelyn Biosciences partners with Queen’s University to develop and manufacture gene therapy AAV9-GM2 to treat GM2 gangliosidoses

    Andelyn Biosciences partners with Queen’s University to develop and manufacture gene therapy AAV9-GM2 to treat GM2 gangliosidoses

    Cellution Biologics completes acquisition of SimpliDerm business for US$ 8 million from Elutia

    Cellution Biologics completes acquisition of SimpliDerm business for US$ 8 million from Elutia

    ACB Gujarat arrested two FDA Officials red-handed in Bharuch accepting a bribe of ₹40,000

    ACB Gujarat arrested two FDA Officials red-handed in Bharuch accepting a bribe of ₹40,000

    US appeals court sides with Sun Pharma in Lipitor antitrust case

    US appeals court sides with Sun Pharma in Lipitor antitrust case

    Counterfeit Cosmetics Are No Longer a Fringe Problem: 4 in 10 Consumers Report Fake Products, Regulatory Silence Raises Serious Questions

    Counterfeit Cosmetics Are No Longer a Fringe Problem: 4 in 10 Consumers Report Fake Products, Regulatory Silence Raises Serious Questions

    Three arrested for illegal sale of mephentermine sulphate injections in Hyderabad

    Three arrested for illegal sale of mephentermine sulphate injections in Hyderabad